Actein Inhibits Tumor Growth and Metastasis in HER2-Positive Breast Tumor Bearing Mice via Suppressing AKT/mTOR and Ras/Raf/MAPK Signaling Pathways
Publication in refereed journal


Times Cited
Altmetrics Information
.

Other information
AbstractHER2-positive breast cancer accounts for 15-20% in breast cancer and 50% of the metastatic HER2-positive breast cancer patients died of central nervous system progression. The present study investigated the effects of actein (a natural cycloartane triterpene) on cells adhesion, migration, proliferation and matrix degradation, and its underlying mechanism in HER2-positive breast cancer cells. Thein vivoeffect of actein on tumor growth and metastasis in MDA-MB-361 tumor-bearing mice as well as the anti-brain metastasis in tail vein injection mice model were also investigated. Our results showed that actein inhibited HER2-positive breast cancer cells viability, proliferation and migration. Actein also induced MDA-MB-361 cells G1 phase arrest and inhibited the expressions of cyclins and cyclin-dependent kinases. For intracellular mechanisms, actein inhibited the expressions of molecules in AKT/mTOR and Ras/Raf/MAPK signaling pathways. Furthermore, actein (15 mg/kg) was shown to exhibit anti-tumor and anti-metastatic activities in MDA-MB-361 breast tumor-bearing mice, and reduced brain metastasis in tail vein injection mice model. All these findings strongly suggested that actein is a potential anti-metastatic agent for HER2-positive breast cancer.
Acceptance Date29/04/2020
All Author(s) ListXiao-Xiao Wu, Grace Gar-Lee Yue, Jin-Run Dong, Christopher Wai-Kei Lam, Chun-Kwok Wong, Ming-Hua Qiu, Clara Bik-San Lau
Journal nameFrontiers in Oncology
Year2020
Month5
Day27
Volume Number10
PublisherFrontiers Media
Article number854
ISSN2234-943X
LanguagesEnglish-United Kingdom
Keywordsactein, metastasis, brain-metastasis, human epidermal growth factor receptor 2 (HER2), HER2-positive breast cancer

Last updated on 2021-22-06 at 00:14